Trulicity is still the market leader with sales of $4.13 billion last year, a rise of 29%, but Ozempic has been gaining ground. Novo Nordisk’s drug grew 142% in 2019 to $1.6 billion.

Trulicity contributed $1.9 billion, up 25%, while COVID-19 antibodies bamlanivimab and etesevimab added another $1.1 billion to the pot and JAK inhibitor Olumiant (baricitinib) grew 59% to $306 ...

WeightWatchers said Tuesday it is filing for Chapter 11 bankruptcy protection to eliminate $1.15 billion in debt and focus on its transition into a telehealth services provider.

View the most recent data and latest information on option chains for Eli Lilly and Company Common Stock (LLY) at Nasdaq.com.